| 1 |
Eid AJ, Ardura MI; AST Infectious Diseases Community of Practice. Human parvovirus B19 in solid organ transplantation: Guidelines from the American society of transplantation infectious diseases community of practice[J]. Clin Transplant, 2019, 33(9): e13535.
|
| 2 |
Long Z, Yu F, Du Y, et al. Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimus[J]. Ann Hematol, 2018, 97(11): 2047-2054.
|
| 3 |
Ozawa K, Ayub J, Kajigaya S, et al. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells[J]. J Virol, 1988, 62(8): 2884-2889.
|
| 4 |
Mühlemann B, Margaryan A, Damgaard PB, et al. Ancient human parvovirus B19 in Eurasia reveals its long-term association with humans[J]. Proc Natl Acad Sci U S A, 2018, 115(29): 7557-7562.
|
| 5 |
Eid AJ, Brown RA, Patel R, et al. Parvovirus B19 infection after transplantation: a review of 98 cases[J]. Clin Infect Dis, 2006, 43(1): 40-48.
|
| 6 |
Hirokawa A, Sawada K, Fujishima N, et al. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group[J]. Br J Haematol, 2015, 169(6): 879-886.
|
| 7 |
Doherty T, Austin SK, Newell B, et al. Mycophenolate mofetil-induced erythroid hypoplasia in a patient with systemic lupus erythematosus[J]. Lupus, 2013, 22(2): 213-215.
|
| 8 |
Patil MR, Choudhury AR, Chohwanglim M, et al. Post renal transplant pure red cell aplasia-is tacrolimus a culprit？[J]. Clin Kidney J, 2016, 9(4): 603-605.
|
| 9 |
Guo YM, Ishii K, Hirokawa M, et al. CpG-ODN 2006 and human parvovirus B19 genome consensus sequences selectively inhibit growth and development of erythroid progenitor cells[J]. Blood, 2010, 115(22): 4569-4579.
|
| 10 |
Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature[J]. Clin Infect Dis, 2013, 56(7): 968-977.
|
| 11 |
Jordan JA. Diagnosing human parvovirus B19 infection: guidelines for test selection[J]. Mol Diagn, 2001, 6(4): 307-312.
|
| 12 |
Lunardi C, Tinazzi E, Bason C, et al. Human parvovirus B19 infection and autoimmunity[J]. Autoimmun Rev, 2008, 8(2): 116-120.
|
| 13 |
Šutová I, Chovancová Z, Litzman J. Adverse effects of immunoglobulin therapy[J]. Vnitr Lek, 2019, 65(2): 131-132.
|
| 14 |
Thornby KA, Henneman A, Brown DA. Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches[J]. Ann Pharmacother, 2015, 49(6): 715-726.
|
| 15 |
Souayah N, Hasan A, Khan HM, et al. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders[J]. J Clin Neuromuscul Dis, 2011, 12(Suppl 4): S1-S10.
|
| 16 |
Jordan SC, Toyoda M, Kahwaji J, et al. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients[J]. Am J Transplant, 2011, 11(2): 196-202.
|
| 17 |
Suzuki S, Osaka Y, Nakai I, et al. Pure red cell aplasia induced by FK506[J]. Transplantation, 1996, 61(5): 831-832.
|
| 18 |
Hirokawa M. Diagnosis and management of pure red cell aplasia[J]. Rinsho Ketsueki, 2015, 56(10): 1922-1931.
|
| 19 |
Srivastava A, Singh V, Kumar D, et al. Does mycophenolate mofetil decrease the recurrent acute rejection in renal transplant recipients[J]. Int Urol Nephrol, 2005, 37(3): 615-619.
|
| 20 |
Lee JJ, Kim MS, Kim YS, et al. The effect of later change or modulation of immunosuppression on long-term renal transplant results[J]. Transplant Proc, 2010, 42(10): 4037-4039.
|
| 21 |
李纳，汤姝，朱振峰，等. 肾移植术后应用咪唑立宾和吗替麦考酚酯的有效性和安全性Meta分析[J]. 中国医院药学杂志，2018, 38(10): 1102-1109.
|
| 22 |
Renoult E, Bachelet C, Krier-Coudert MJ, et al. Recurrent anemia in kidney transplant recipients with parvovirus B19 infection[J]. Transplant Proc, 2006, 38(7): 2321-2323.
|